Comparing the prognosis of in vitro fertilization/intracytoplasmic sperm injection and embryo transfer between unexplained primary infertility patients with repeated artificial insemination with homologous semen failure and tubal infertility patients

Abstract Background Both in vitro fertilization and embryo transfer (IVF‐ET) and intracytoplasmic sperm injection and embryo transfer (ICSI‐ET) have been recommended for unexplained primary infertility after recurrent artificial insemination with homologous semen failure (UAIHF), but few studies focused on the safety and efficiency of the IVF/ICSI‐ET technique for these patients. In this study, we compared the IVF/ICSI‐ET outcomes and perinatal and postnatal complications between UAIHF patients and tubal infertility (TI) patients. Methods We conducted a retrospective study of UAIHF and TI patients who underwent IVF/ICSI‐ET at Guangxi Reproductive Medical Center, the First Affiliated Hospital of Guangxi Medical University from January 2012 to March 2021. After propensity score matching (PSM), we analyzed the IVF/ICSI‐ET outcomes and rates of perinatal and postnatal complications. Results PSM analysis revealed that the baselines of age, infertility duration, and body mass index were comparable. The fertilization method was significantly different between the two groups. Through IVF/ICSI‐ET, UAIHF patients had a similar clinical outcome compared to TI patients. Regarding perinatal and postnatal complications, the incidence of premature rupture of membranes (PROM) (7.54% vs. 3.17%, p = 0.030) was significantly higher in UAIHF patients. Conclusions UAIHF patients could achieve satisfying pregnancy outcomes by IVF/ICSI‐ET. ICSI‐ET did not seem to improve the clinical outcomes of UAIHF patients compared to those of TI patients who underwent IVF‐ET, which might be related to possible underlying diseases in these patients. In addition, the incidence of PROM was significantly higher in UAIHF patients, which might be related to the ICSI technique used and uncertain potential idiopathic diseases associated with unexplained infertility patients. Trial registration: Chinese Clinical Trial Registry, ChiCTR2200057572. Registered 15 March 2022.